NCT00813826View on ClinicalTrials.gov

Efficacy and Safety Study of SLC022 in Treating Pain Associated With Post Herpetic Neuralgia

PHASE2UnknownINTERVENTIONAL
Enrollment

204

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

October 31, 2009

Study Completion Date

November 30, 2009

Conditions
Postherpetic Neuralgia
Interventions
DRUG

SLC022

SLC022 150 mg capsule, 900mg daily dose

DRUG

Placebo

Placebo capsule, TID

Trial Locations (19)

14618

Rochester

16602

Altoona

19139

Philadelphia

19611

West Reading

20301

Brockton

27103

Winston-Salem

30060

Marietta

32806

Orlando

33324

Plantation

45429

Kettering

60523

Oak Brook

68134

Omaha

71030

Shreveport

75230

Dallas

77074

Houston

78229

San Antonio

84047

Midvale

85635

Sierra Vista

92691

Mission Viejo

Sponsors
All Listed Sponsors
lead

Solace Pharmaceuticals

INDUSTRY